News | October 06, 2025
Evofem's SOLOSEC submitted for regulatory approval in the UAE
Marks first international filing for Evofem’s single-dose oral treatment
Marks first international filing for Evofem’s single-dose oral treatment
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
India currently hosts more than 10,075 biotech startups
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
Subscribe To Our Newsletter & Stay Updated
